Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 50.5 EUR 0.2% Market Closed
Market Cap: 10.4B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Recordati Industria Chimica e Farmaceutica SpA
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Recordati Industria Chimica e Farmaceutica SpA
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Other Liabilities
€21.3m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
0%
Newron Pharmaceuticals SpA
SIX:NWRN
Other Liabilities
€1.7m
CAGR 3-Years
27%
CAGR 5-Years
6%
CAGR 10-Years
N/A
P
Pierrel SpA
MIL:PRL
Other Liabilities
€5.2m
CAGR 3-Years
62%
CAGR 5-Years
28%
CAGR 10-Years
14%
Friulchem SpA
MIL:FCM
Other Liabilities
€1.1m
CAGR 3-Years
0%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Other Liabilities
€833k
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
N/A
No Stocks Found

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Market Cap
10.4B EUR
Industry
Pharmaceuticals

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
58.09 EUR
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Recordati Industria Chimica e Farmaceutica SpA's Other Liabilities?
Other Liabilities
21.3m EUR

Based on the financial report for Sep 30, 2024, Recordati Industria Chimica e Farmaceutica SpA's Other Liabilities amounts to 21.3m EUR.

What is Recordati Industria Chimica e Farmaceutica SpA's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
0%

Over the last year, the Other Liabilities growth was 11%.

Back to Top